Enterprise Therapeutics, a UK-based life sciences firm targeting lung and mucus conditions, has closed its series A round at £4m ($6.3m).
The Sussex University spin-out previously raised £1.6m in February 2015 from life sciences investor Epidarex, which topped up its investment in the round by £400,000 along with Imperial Innovations, the technology transfer office of Imperial College London, which provided the additional £2m.
Enterprise Therapeutics, founded in May 2014, is seeking to develop therapies which target the causes of respiratory…
